Lung Cancer.pdf

Table 9–7. Non-Platinum-Containing Doublets versus Platinum-Containing Doublets
Median 1-Year
Study and No. of Response Survival Survival
Treatment Regimen Patients Rate Time Rate P
Kosmidis (2000)
Carboplatin paclitaxel 165 29% 10.7 months 41%
Gemcitabine paclitaxel 164 37% 12.3 months 51% .047
(P .17)
GEPC 98–02 (Alberola, 2001)
Cisplatin gemcitabine 166 43% 8.7 months 35%
Cisplatin gemcitabine vinorelbine 176 38% 7.9 months 31%
Gemcitabine vinorelbine followed by 175 26% 8.1 months 35%
vinorelbine or ifosfamide
EORTC 8975 (Van Meerbeeck, 2001)
Cisplatin paclitaxel 153 31% 8.1 months 35.5%
Cisplatin gemcitabine 158 36% 8.8 months 32.6% .9*
(P .3)*
Gemcitabine paclitaxel 157 27% 6.9 months 26.5% .09†
(P .5)†
* Cisplatin and paclitaxel versus cisplatin and gemcitabine.
† Cisplatin and paclitaxel versus gemcitabine and paclitaxel.
Treatment of Patients with Advanced Non–Small Cell Lung Cancer 175